The Procter Gamble Company

The Cleveland Clinic Foundation

Other

Duke University

The Procter & Gamble Plaza

John August Wos

Biswanath De

David Lindsey Soper

Mitchell Anthony DeLong

Jack Snyder Amburgey, Jr

Stanley Leon Hazen

Yili Wang

Jose Carlos Garcia-Garcia

George Franklin Gerberick

Haiyan George Dai

Michael Reilly

Michael Christopher Laufersweiler

Steven Victor O'Neil

Kofi Abeka Oppong

David Blair Cody

Thomas Prosser Demuth, Jr

Mark Robert Sivik

Mitchell Anthony deLong

Frank Hallock Ebetino

David Thomas Stanton

Thomas Alfred Inglin

Angela Jane Deutsch

Xiaodong Gu

Jodie Michele Reed

Johan Smets

Phillip Kyle Vinson

Alan David Willey

Bryan Patrick Murphy

Philip Andrew Sawin

Steven Daryl Smith

John Michael Gardlik

Yonas Gizaw

John M Janusz

Susana Fernandez Prieto

Robb Richard Gardner

Hiroshi Oh

Randy Purnell Washington

Rebecca Ann Langevin

Garry Steven Garrett

Rafael Ortiz

Jamie Angel Reed

Todd Laurence Underiner

Jacob Robert Adams

Randall Thomas Reilman

Mark Gregory Solinsky

Wolfgang Edgar Huhn

Timothy Bates

Mate Debreczeni

Bartosz Tylkowski

Marta Giamberini

Jian Chen

Jodie Michelle Reed

Xuewei Liu

Lee Arnold Schectman

Cynthia Jean Miley

Heath A Frederick

Tim Bates

Xiandong Gu

John Michael Janusz

A hand dishwashing detergent composition includes from 5.0% to 50% of a surfactant system by weight of the liquid hand dishwashing detergent composition. The surfactant system includes an anionic surfactant. The anionic surfactant includes an alkyl sulfate anionic surfactant and glyceryl acetal sulfate surfactant. The glyceryl acetal sulfate surfactant is selected from glyceryl acetal sulfate having the formula I or formula II or salts thereof, and mixtures thereof.

Liquid hand dishwashing detergent composition

A method of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO by providing a composition comprising a compound set forth in Formula (I): 

Methods for inhibiting conversion of choline to trimethylamine (TMA)

A method for shaping keratin fibres comprising: providing a crosslinking composition, wherein the crosslinking composition comprises: an active agent, wherein the active agent comprises a functional group selected from the group consisting of: &#x2014;C(&#x2550;O)&#x2014;, &#x2014;C(&#x2550;O)&#x2014;H, and &#x2014;C(&#x2550;O)&#x2014;O&#x2014;; and wherein the active agent is not an acid; and wherein the active agent has a molecular weight of 500 g/mol or less; a photocatalyst; a cosmetically acceptable carrier; and applying the crosslinking composition to keratin fibres, mechanically shaping the keratin fibres with an appliance or implement, and exposing the composition to electromagnetic radiation having a wavelength of from about 300 nm to about 750 nm. Also a related composition, use, kit and process.

Shaping keratin fibres using an active agent comprising a functional group selected from the group consisting of: -C(=O)-, -C(=O)-H, and -C(=O)-O-

The invention provides a method of inhibiting the conversion of carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): Wherein the compound is administered in an amount effective to inhibit conversion of carnitine to TMA in the individual.

Methods for inhibiting conversion of carnitine to trimethylamine (TMA)

The invention provides one or more methods of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline in the individual.

A method of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual by providing a composition comprising a compound set forth in Formula (I): 

The invention provides a method of inhibiting the conversion of choline or carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual a composition comprising a compound set forth in FORMULA (I): The invention also provides for a method of inhibiting the production of TMA by bacteria comprising administering to the individual a composition comprising a compound set forth in FORMULA (I) wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline or carnitine in the individual.

Compounds and methods for inhibiting production of trimethylamine

The present application relates to encapsulates, compositions, products comprising such encapsulates, and processes for making and using such encapsulates. Such encapsulates comprise a core comprising a perfume and a shell that encapsulates said core, such encapsulates may optionally comprise a parametric balancing agent, such shell comprising one or more azobenzene moieties.

Encapsulates

A cleaning composition may comprise a pH-switchable sudsing system and a cleansing system. The pH-switchable sudsing system may comprise a primary sudsing agent in combination with a pH-switchable co-surfactant. The pH-switchable co-surfactant is selected from diamine molecules having a general formula RR&#x2014;N&#x2014;R&#x2014;N(CH)X, where Ris a linear or branched Cto Chydrocarbyl, Ris a linear or branched Cto Chydrocarbyl, Ris a linear or branched Cto Chydrocarbylene, and X is a counteranion. The tertiary amine nitrogen of the pH-switchable co-surfactant has a pKvalue. When the tertiary amine nitrogen is unprotonated, the pH-switchable co-surfactant may provide a suds-boosting effect in washing solutions at a washing pH above the pK. When the tertiary amine nitrogen is protonated, the pH-switchable co-surfactant may provide a suds-reducing benefit in rinse waters at a rinse pH below the pK.

Cleaning compositions comprising pH-switchable amine surfactants

A process for synthesizing 2-methoxymethyl-1,4-benzenediamine, its derivatives of formula (IV) and the salts thereof, which comprises a reductive amination step. The preferred final product is 2-methoxymethyl-1,4-benzenediamine of formula (IV-a).  These compounds may be used as primary intermediates in compositions for dyeing keratin fibers.

Process for the preparation of 2-methoxymethy1-1,4-benzenediamine, its derivatives thereof and the salts thereof

Compounds having the general structure: which are useful for the treatment of a variety of diseases and conditions, such as bone disorders.

C16 unsaturated FP-selective prostaglandins analogs

The present invention relates to novel compounds, compositions comprising said compounds, and uses thereof, said compounds having the formula: 

Interleukin-1&#x3b2; converting enzyme inhibitors

The present invention relates to interleukin-1&#x3b2; converting enzyme inhibitors having the formula:

The present invention relates to compounds which comprise a 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring. The compounds, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula:wherein preferably R is substituted aryl, W is a pendant unit having the formula:-L-QL is a linking unit, Q is preferably a cyclic hydrocarbyl unit; Wis preferably a carbocyclic unit and Wis a heteroatom comprising unit.

Melanocortin receptor ligands

The present invention relates to novel compounds, compositions comprising said compounds, and uses thereof, said compounds having the formula:wherein each X is independently selected from:

Interleukin converting enzyme inhibitors

Growing community of inventors

Maineville, OH, United States of America

John August Wos